Comparative Pharmacology
Head-to-head clinical analysis: PALBOCICLIB CAPSULES versus RIBOCICLIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALBOCICLIB CAPSULES versus RIBOCICLIB.
PALBOCICLIB CAPSULES vs RIBOCICLIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), preventing phosphorylation of retinoblastoma protein, thereby blocking cell cycle progression from G1 to S phase.
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Selectively inhibits CDK4 and CDK6, leading to reduced phosphorylation of retinoblastoma protein, G1-to-S phase cell cycle arrest, and decreased proliferation of estrogen receptor-positive breast cancer cells.
125 mg orally once daily for 21 days followed by 7 days off treatment, in combination with an aromatase inhibitor or fulvestrant.
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment, in combination with an aromatase inhibitor or fulvestrant.
None Documented
None Documented
Clinical Note
moderateRibociclib + Gatifloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Gatifloxacin."
Clinical Note
moderateRibociclib + Levofloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Levofloxacin."
Clinical Note
moderateRibociclib + Sparfloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Sparfloxacin."
Clinical Note
moderateRibociclib + Haloperidol
Mean terminal half-life is 29 hours (range 26–38 hours) at steady state, supporting once-daily dosing.
Terminal elimination half-life is 32.0 hours (range 29.2–40.4 hours), supporting once-daily dosing.
Primarily hepatic metabolism via CYP3A4 and SULT2A1, with 74.1% of dose recovered in feces (56.5% as unchanged drug, 17.6% as metabolites) and 17.5% in urine (1.2% unchanged). Minor biliary excretion contributes to fecal elimination.
Primarily hepatic metabolism (CYP3A4) with fecal excretion as major route (69% of dose as metabolites, 23% unchanged in feces); renal excretion accounts for approximately 12% (primarily as metabolites, <1% unchanged).
Category D/X
Category C
CDK4/6 Inhibitor
CDK4/6 Inhibitor
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Haloperidol."